ewsba.se
(RTTNews) - Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period.
The company posted revenue of $200.4 million for the three months ended March 31, 2026, up from $195.9 million a year earlier. Net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter. Loss per share was $0.36 for the quarter, while weighted average shares outstanding stood at 93.7 million.
Operating loss came in at $30.7 million, up from $29.0 million last year, as total operating expenses increased to $168.3 million from $163.2 million. The higher expenses were driven in part by research and development costs of $27.1 million and sales and marketing expenses of $73.6 million.
MYGN is currently trading after hours at $4.47, down $0.56 or 11.13 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.